“Staying Forever Young”: H2 Global Group Brings a Hydrogen Standard to the Longevity Sector

“Staying Forever Young”: H2 Global Group Brings a Hydrogen Standard to the Longevity Sector

by | Dec 4, 2025 | Health

Prague, 3 December 2025 (PROTEXT) – The longevity market is experiencing a global boom. More and more people are becoming aware of the vast possibilities of today’s modern world, and the desire to reach an advanced age while staying free of major health issues and in good physical condition is growing. What was until recently an area reserved mainly for biohackers and enthusiasts is becoming a serious multidisciplinary business attracting investors, medical and pharmaceutical groups, and luxury wellness brands. According to expert estimates, the global longevity market could reach a value of around USD 1.87 trillion by 2034. Projects that manage to combine clinical credibility, measurable results, and premium services will come out on top. For several years, the technological standard in this field has been set by the Czech group H2 Global Group, specializing in the use of molecular hydrogen in medicine, longevity, beauty, and sports, supported by its subsidiaries H2 Medical Technologies, H2 Pharm, and H2 Longevity Lifestyle.

From “Blue Zones” to a Modern and Innovative Approach to Geriatrics

Today’s concept of longevity builds both on inspiration from so-called “Blue Zones”—regions with a high proportion of long-lived inhabitants—and on modern “geroscience,” which describes aging as a biological process influenced, among other factors, by oxidative stress, chronic inflammation, and mitochondrial dysfunction. According to numerous scientific studies, molecular hydrogen plays a very important role in these mechanisms. Many clinical studies and expert papers indicate that it acts as a selective antioxidant, has anti-inflammatory and mitochondria-protective effects, and in preclinical and clinical studies shows significant potential in cognitive health, neurodegenerative diseases, physical performance, and regeneration. Hydrogen is not a miraculous “elixir of immortality,” but a promising bioactive molecule that fits well into the philosophy of safe, long-term, and measurable support for lifespan and healthspan.

 

H2 Global Group: A Czech Innovator in Molecular Hydrogen

H2 Global Group, headquartered in the Czech Republic, was founded with the goal of building a complete technological and product ecosystem around molecular hydrogen. The group employs physicians, scientists, and pharmacists, has its own R&D facilities, and works closely with Japanese professor Shigeo Ohta—considered the father and founder of hydrogen biomedicine—who is also a co-owner of the company. The company’s portfolio includes solutions for medicine, neuroscience, beauty and wellness, spas and medical centers, sports teams, and corporate wellness programs.

 

H2 Medical Technologies and Controlled Hydrogen Therapy

A key role in the group’s MedTech segment is played by its subsidiary H2 Medical Technologies. It develops and manufactures safe and efficient molecular hydrogen generators based on modern SPE/PEM technology, capable of producing ultra-pure hydrogen for safe inhalation in both clinical and home environments. A major milestone is the prototype of the world’s first hydrogen generator with which the company will seek registration as the world’s first hydrogen-based medical device. It will also be used in the first clinical trial in the Czech Republic, approved by the State Institute for Drug Control (SÚKL), involving molecular hydrogen inhalation for individuals with mild cognitive impairment (MCI), a condition that often precedes Alzheimer’s dementia.

This clinical study will begin in early 2026 and aims to evaluate the safety and efficacy of controlled hydrogen therapy in MCI patients. Recruitment is currently underway, and the company is looking for suitable volunteers diagnosed with mild cognitive impairment. Applicants must meet these basic criteria: age 50–80, overall good health, a diagnosis of mild cognitive impairment or mild to moderate dementia, and ideally residence in Ostrava or the surrounding area where the study will take place. Participation does not guarantee any health benefits and should not be considered a substitute for standard treatment. Interested individuals may apply until 23 December 2025 at: david.skoloudik@H2medical.com.

This step elevates the use of molecular hydrogen from a supplementary wellness tool to a serious medical instrument of the near future, with potential not only in cognitive health and dementia prevention. This study follows the European patent EP3701956B1 “Prophylactic or Therapeutic Agent for Dementia,” authored by Professor Ohta and held by H2 Global Group. The patent describes the use of molecular hydrogen in neurodegenerative conditions including dementias and gives the Czech Republic a unique position on the global stage.

 

H2 Longevity® Center in Ostrava

Building on successful scientific research, the H2 Longevity® Center was recently opened in Ostrava. This next-generation center combines molecular hydrogen inhalation using H2 Medical Technologies devices, light therapy, hydrogen hydration through H2 Premium Hydrogen Water, specialized hydrogen dietary supplements, and education on regeneration and healthy longevity. The center functions as a showroom for distributors, investors, and partners, as well as for customers. The group plans to use the acquired know-how to build a network of partner H2 Longevity® concepts in other cities and countries.

A Strategic Global Partner with a Unique Hydrogen Solution

A major part of the business also involves collaboration with partners seeking to launch their own premium hydrogen-based longevity product lines. Interest is coming from various countries across Europe and beyond. These include medical centers, wellness hotels, private clinics, and other facilities focused on biohacking, longevity, body care, and overall regeneration. Partners appreciate the option to create their own premium brand as well as the ability to leverage the company’s existing portfolio. H2 Global Group thus acts as a strategic global partner—not just a manufacturer, but a leader of the entire segment—setting the direction for hydrogen technologies while supporting brand building and the growth of its distribution partners.

 

Hydrogen as a Pillar of Longevity

The group offers partners the opportunity to build a comprehensive system of hydrogen-based care with emphasis on maximum safety and therapeutic efficacy. The system includes professional training on installation, handling, and use of molecular hydrogen inhalation devices; proven procedures and protocols; incorporation of hydrogen water into hydration routines; and hydrogen dietary supplements to enhance therapy outcomes. Technical support, including warranty and post-warranty service, is guaranteed. The modular and scalable system can be tailored to clients’ needs and local market specifics, while drawing on scientific and practical knowledge and accumulated experience.

Opportunities for Service Providers, Distributors, and Investors

For partners in healthcare, wellness, spa, and cosmetics, H2 Global Group represents an opportunity to participate in creating a new standard in the rapidly growing longevity segment. This includes local hydrogen zones in clinics, hotels, wellness centers, and spas, as well as complete portfolios of functional hydrogen products under a private label. For investors, the combination of proprietary medical research and development, international patent protection, existing clinical evidence in molecular hydrogen use, global scalability through exclusive partnerships and licensing models, and the strong trend toward longevity, prevention, and health optimization makes for an attractive proposition.

H2 Global Group is expanding its partner network and entering key foreign markets. It is opening cooperation opportunities for investors and strategic partners who want to be part of building a modern global longevity infrastructure using a proven and effective tool for achieving the best possible outcomes. If you wish to include cutting-edge hydrogen technologies in your portfolio and build a strong and respected brand using the best the market has to offer—while participating in the growth of an exceptionally promising global segment—now is the right moment to join.

The report is available to the public on the website here:

Company Contact: H2 Global Group
www.H2global.group
www.H2Vibe.cz
www.H2invest.cz

Source: H2 Global Group

ČTK Connect provides an image attachment available at https://www.protext.cz.

PROTEXT

 

 

 

 

 

 

 

 

 

 

 

 

 

H2 Global Group – Press Conference at ČTK

H2 Global Group – Press Conference at ČTK

by | Dec 3, 2025 | Health

Molecular Hydrogen and Dementia Prevention: Czech Research Heads into Its First Clinical Study

Today, on 12 November 2025, a press conference of H2 Medical Technologies, part of the H2 Global Group, was held at the ČTK Press Centre, where we announced a major milestone – the approval of the first clinical study by SÚKL in the Czech Republic focused on the inhalation of molecular hydrogen in patients with mild cognitive impairment (MCI).

Mild cognitive impairment is a condition that often precedes Alzheimer’s dementia. The possibility of early intervention at this stage is crucial – and this is precisely where molecular hydrogen may play an important role. The study was also approved by the Ethics Committee of the University Hospital Ostrava, where it will be conducted.

You can find the full ČTK article and the press conference recording here:

Aktuálně.cz
https://www.aktualne.cz/zive-molekularni-vodik-pro-prevenci-i-lecbu-kognitivnich-por/r~fd46418ebeea11f080bfac1f6b220ee8/

Reflex
https://www.reflex.cz/clanek/zajimavosti/132854/zive-molekularni-vodik-pro-prevenci-i-lecbu-kognitivnich-poruch.html

České noviny
https://www.ceskenoviny.cz/zpravy/2745785

Frekvence 1
https://www.frekvence1.cz/zpravy/tiskove-konference/zive-vyrocni-tiskova-konference-skupiny-cez-kopie.shtml

Blesk pro ženy
https://prozeny.blesk.cz/clanek/pro-zeny-zdravi-zdravi/826371/zive-molekularni-vodik-pro-prevenci-i-lecbu-kognitivnich-poruch.html

Hospodářské noviny
https://domaci.hn.cz/c1-67811780-zive-molekularni-vodik-pro-prevenci-i-lecbu-kognitivnich-poruch

How will the study be conducted?

The approved clinical study is designed to evaluate as precisely as possible the safety and potential benefits of inhaling molecular hydrogen in patients with cognitive impairment.

Basic study parameters:

  • Start: January 2026

  • Duration: 6 months

  • Number of participants: approx. 30 patients

  • Age range: 50–80 years

Study procedure:

  • inhalation of molecular hydrogen for 1 hour per day,

  • 5× per week for 3 months,

  • followed by a 3-month monitoring phase without active intervention.

The study will track:

  • safety of molecular hydrogen inhalation,

  • changes in biochemical markers,

  • impact on cognitive functions,

  • and quality of life from the patients’ perspective.

Building on Japanese research and a European patent

This clinical study builds on the work of Professor Shigeo Ohta in Japan, one of the co-founders of H2 Global Group. His research led to the granting of the European patent EP3701956B1, covering the prophylaxis and treatment of dementia using molecular hydrogen.

Thanks to this patent, our development is based on a strong scientific and intellectual-property foundation, which enhances:

  • the credibility of the technology,

  • our position in the field of innovative therapeutic approaches,

  • and the future potential for global application.

Czech innovation with global impact

Approval of the clinical study is an important step towards our goal:
to introduce, in 2026, the world’s first medical device using molecular hydrogen, developed in the Czech Republic.

We then plan to expand it to other EU countries, the USA, and Asia. This milestone:

  • strengthens our scientific credibility,

  • reinforces our regulatory standing,

  • and confirms that Czech know-how can play a role in global medicine, particularly in the field of neurodegenerative diseases such as Alzheimer’s dementia.

We are seeking volunteers for the clinical study

As part of today’s announcement, we are also calling for volunteers who wish to actively participate in the research and contribute to improving future options for the prevention and treatment of dementia.

Who are we looking for?

  • individuals aged 50–80,

  • in generally good health,

  • diagnosed with mild cognitive impairment or mild to moderate dementia,

  • ideally from Ostrava and the surrounding area (the study is conducted at University Hospital Ostrava).

How to apply?
Interested participants can apply until 30 November 2025 at:
📧 david.skoloudik@H2medical.com

Our thanks and our vision

This step would not have been possible without the support of our partners, experts, and investors who believe that molecular hydrogen can become a new, safe, and non-invasive tool in combating the devastating effects of dementia.

Thank you to everyone who supports us on this journey and helps us develop Czech innovation with global reach.

H2 Global Group – Our Story

H2 Global Group – Our Story

by | Dec 3, 2025 | Health

It has been nearly 14 years since David Maršálek happened to meet Professor Dušan Miljković in the USA – the man who first introduced a hydrogen-based dietary supplement to the world. This moment set in motion a journey that has led to a project with global ambitions today.

Over time, other top scientists joined him – Professor Shigeo Ohta from Japan, Professor Jan Slezák, a team from Palacký University, and other experts from Europe, the USA, and Japan. This is how H2 Global Group was created, followed later by H2 Medical Technologies, focused on research and development of molecular hydrogen in medicine.

From a single idea to a breakthrough clinical study

What began as an interest in dietary supplements gradually revealed that molecular hydrogen has potential in medicine as well – especially in the field of neurodegenerative diseases. Thanks to an international team of experts, the idea emerged to create the world’s first medical device based on molecular hydrogen.

And in 2025, a major breakthrough came:

  • SÚKL approved the first clinical study in the Czech Republic evaluating the safety of inhaling molecular hydrogen in patients with mild cognitive impairment.

  • The study builds on successful Japanese research by Professor Ohta, who is also behind the European patent EP3701956B1 for the prevention and treatment of dementias.

A Czech project with global reach

We collaborate on this project with leading scientific teams, including Professor MUDr. David Školoudík and experts from Palacký University. Our vision is to contribute to the medicine of the future—one that focuses not only on treatment, but above all on the prevention of civilization diseases.

Although we are a small country, today we have something exceptional:
patents, technology, and an international team capable of setting the direction for global medicine.

The full article titled:

A Czech Breakthrough in Global Medicine: Molecular Hydrogen Becomes the Subject of the First Clinical Study of Its Kind in the Czech Republic

https://www.ceskenoviny.cz/tiskove/zpravy/cesky-prulom-do-svetove-mediciny-molekularni-vodik-je-tematem-prvni-klinicke-studie-sveho-druhu-v-cr/2747234

“Alzheimer’s dementia: a breakthrough gentle Czech solution turns a problem into an opportunity. And investors don’t want to miss out.”

“Alzheimer’s dementia: a breakthrough gentle Czech solution turns a problem into an opportunity. And investors don’t want to miss out.”

by | Dec 3, 2025 | Health

Precisely in this field comes news from the Czech Republic with the potential to place the country on the map of world medicine. The State Institute for Drug Control (SÚKL) has approved the first clinical study in the Czech Republic that will evaluate the safety of inhaling molecular hydrogen in patients with mild cognitive impairment, a frequent precursor of Alzheimer’s dementia. The project is led by the Czech company H2 Medical Technologies, part of the H2 Global Group.

“We want to bring high-quality data and open a discussion about how molecular hydrogen can fit into the medicine of the future. Our solution represents an entirely new, non-invasive, and safe method that has the potential to become an innovative approach, whose effects on neurodegenerative diseases are now the subject of clinical testing,” says PharmDr. Milan Krajíček, Director of Research, Development and Production and co-founder of H2 Global Group.

Why we can no longer afford to wait

The development of Alzheimer’s disease is driven by a combination of factors: older age and genetic load, cardiovascular risks (high blood pressure, diabetes, obesity, smoking), unhealthy lifestyle, lack of movement and sleep, long-term stress, and processes in the brain such as oxidative stress and inflammation. The result is not just “forgetfulness” but a gradual loss of independence and enormous pressure on families and the care system.

“From a neurologist’s perspective, this is no longer just a medical issue, but a major social topic. If we don’t start addressing it actively today, a very difficult future awaits us,” warns Professor MUDr. David Školoudík, Ph.D., a neurologist who will lead this groundbreaking study.

After the COVID crisis, a global “tsunami of demand” is growing for diagnostics and care, specialized beds, trained personnel, and home and community care. Dementia is shifting from a marginal part of geriatrics to the center of social and economic debate for the coming decades.

Molecular hydrogen: a Czech patent with global ambition

Molecular hydrogen (H₂) is a gas naturally occurring in the body that is recently attracted attention from scientists worldwide. Thousands of studies describe its antioxidant, anti-inflammatory, and cell-protective potential and its ability to influence energy metabolism. Experts do not view it as a “miracle drug” but as a modulator of cellular processes and a promising complement to other health-care approaches.

“We see molecular hydrogen as a tool that can gently influence cellular processes. That is why we need more high-quality clinical data to know exactly where it makes sense,” says Professor Shigeo Ohta from Japan, globally regarded as the father and founder of molecular hydrogen research and co-founder of H2 Global Group.

A significant milestone is the European patent EP3701956B1, “Prophylactic or therapeutic agent for dementia”, authored by Professor Ohta and held by H2 Global Group. The patent describes the use of molecular hydrogen in neurodegenerative diseases, including dementias, giving the Czech Republic a unique position on the global scene.

SÚKL-approved clinical study: when science, medicine, and business come together

This patent now forms the basis for the first clinical study of its kind in the Czech Republic, approved by SÚKL and the Ethics Committee of University Hospital Ostrava. The study will evaluate the safety of inhaling molecular hydrogen in patients with mild cognitive impairment (MCI). It will begin in January 2026 and last six months. Approximately 30 patients aged 50–80 will participate. They will inhale molecular hydrogen for one hour a day, five days a week, for three months, followed by three months of monitoring, including cognitive tests, selected biochemical parameters, and quality-of-life assessments.

“We don’t want to promise miracles; we want to obtain more data,” summarizes Professor Školoudík. “Only then will we be able to responsibly say what role molecular hydrogen inhalation may have for this group of patients.”

Once evaluated, the results will be published in professional journals and become another step toward making the Czech Republic the birthplace of the world’s first registered medical device using molecular hydrogen.

Call for participation: help yourself, your family, and future generations

H2 Medical Technologies is launching a public call for volunteers who wish to participate in the study and meet basic criteria: age 50–80, overall good health, a diagnosis of mild cognitive impairment, or mild to moderate dementia, and ideally residence in Ostrava or its surroundings. Participation in this study does not guarantee any health benefit and should not be viewed as a substitute for standard treatment. Interested individuals can apply until 23 December 2025 at: david.skoloudik@H2medical.com

H2 Global Group is a medical-technology group that develops, manufactures, and exclusively supplies innovative and safe products and devices using molecular hydrogen. Today, its solutions are used by spas and wellness centers, sports clubs and elite athletes, private clinics, cosmetic and beauty sectors, corporate health-care programs, and increasingly also ordinary households. It collaborates with physicians, therapists, universities, and scientific teams in the Czech Republic and abroad. It holds several patents and utility models and aims to register the world’s first medical device with molecular hydrogen in the Czech Republic, followed by expansion worldwide.

“When you are healthy, you have thousands of problems to solve. When you become ill, only one remains – how to get well,” says David Maršálek, founder and CEO of H2 Global Group, who introduced molecular hydrogen to the Czech Republic—and later other European countries—14 years ago as the world’s first food supplement of its kind. Since then, through ongoing research, development, and new generations of products and devices, molecular hydrogen has entered Czech homes, companies, spas, clinics, and other places where people seek gentle ways to support their health, vitality, and longevity.

“Despite thousands of published studies and expert articles on molecular hydrogen, we must remain humble. Our duty is to distinguish between marketing and real evidence-based medicine,” emphasizes PharmDr. Milan Krajíček. “That is why we invest in regulated research, clinical studies, and cooperation with top institutions,” he adds.

H2 Global Group thus integrates several layers of social responsibility:
– scientific (systematic research and clinical testing),
– ethical (cooperation with SÚKL and ethics committees, emphasis on patient safety),
– economic (the growing market for medical technologies and preventive medicine),
– and local (innovation developed in the Czech Republic but aimed at patients worldwide).

A unique opportunity for investors to be present at the birth of the ‘hydrogen-era medicine’

Alzheimer’s dementia and other cognitive disorders represent one of the largest future markets—not only in medicine, but also in services, technology, and long-term care. Any solution that can improve patients’ quality of life, delay loss of independence, or reduce caregiver burden has enormous social and economic impact.

Many Czech investors have already seized this opportunity by becoming part of H2 Global Group and contributing to the development of the “medicine of the future”. After the COVID crisis, global demand for innovative MedTech and HealthTech solutions has been rising—solutions that make care more efficient, support prevention, and also focus on active longevity, helping people not only live longer but live better. Additional investors can now join at this decisive stage, at the moment when patent-protected know-how, regulated clinical research, worldwide market demand, and Czech technology with global potential meet in a single project—precisely what investors most often seek.

Being there when a new Czech medical story is written

Alzheimer’s dementia dramatically affects the lives of patients and their loved ones, and experts warn that without active solutions, it will become a deep social and economic problem. The H2 Medical Technologies project and the long-term activities of H2 Global Group show that even a relatively small country can generate an initiative that moves global medicine forward and places social responsibility at the heart of business.

“Now is the time to decide who and how will be part of this—whether as an investor, expert, patient, family caregiver, or future user of molecular hydrogen technologies,” concludes Maršálek.

Media & investor contact:
H2 Global Group / H2 Medical Technologies / H2 Investment
www.H2Global.group, www.H2Vibe.cz, www.H2invest.cz

Czech Breakthrough in Medicine: H2 Global Group Receives Regulatory Approval for Hydrogen Clinical Study — New Era in Alzheimer’s Therapy Begins

Czech Breakthrough in Medicine: H2 Global Group Receives Regulatory Approval for Hydrogen Clinical Study — New Era in Alzheimer’s Therapy Begins

by | Oct 26, 2025 | Alzheimer, Health, Neurology, Spa

European innovation leader H₂ Global Group today announced that its subsidiary H₂ Medical Technologies has received official approval from The State Institute for Drug Control (SÚKL) to initiate a clinical study focused on molecular hydrogen inhalation therapy for patients with mild cognitive impairment (MCI), an early stage of Alzheimer’s disease.

This milestone marks a historic achievement for Czech and European biotechnology, as it represents Europe’s first fully approved clinical trial investigating non-invasive hydrogen inhalation as a neuroprotective therapy.

From Japanese discovery to Czech clinical practice

The project is based on pioneering research by Professor Shigeo Ohta, co-founder of H₂ Global Group and widely regarded as the founding father of therapeutic hydrogen medicine. Professor Ohta personally transferred his European patent (EP 3701956 B1), titled “Prophylactic or Therapeutic Agent for Dementia,” to the Group.

“Launching a clinical study that directly builds on Professor Ohta’s patent is both an honor and a responsibility,” said PharmDr. Milan Krajíček, co-founder of H₂ Global Group. “This milestone proves that Czech innovation and research have truly a global relevance.”

New hope for Alzheimer’s prevention and treatment

“While several antibody-based drugs have been approved to slow Alzheimer’s progression, there is still no widely available, safe, and effective non-invasive treatment,” said David Maršálek, founder and CEO of H₂ Global Group. “Our goal is to offer patients and physicians a gentle, accessible, and scientifically validated solution.”

The study will begin in January 2026 in cooperation with Professor David Školoudík, M.D., Ph.D., one of the Czech Republic’s leading neurologists. The six-month project aims to achieve the world’s first regulatory registration of a medical device utilizing molecular hydrogen.

About H₂ Global Group

H₂ Global Group is a European innovation group connecting research, development, manufacturing, and practical application of molecular hydrogen technologies across healthcare, wellness, sports, cosmetics, and veterinary sectors.

Under the leadership of David Maršálek, the group has built a vertically integrated ecosystem, from R&D and product innovation to manufacturing and global distribution. With an estimated company valuation exceeding USD 77 million, expanding patent portfolio, and strategic partnerships worldwide, H₂ Global Group ranks among Europe’s most progressive biotechnology innovators. For more information, visit www.H2Global.group

Source: https://apnews.com/press-release/pr-newswire/czech-breakthrough-in-medicine-h%E2%82%82-global-group-receives-regulatory-approval-for-hydrogen-clinical-study-new-era-in-alzheimers-therapy-begins-0ed2505a01c678655fef658f53f93c11?utm_source=ecomail&utm_campaign=2025_10_24_globalni_medialni_ohlas_schvaleni_klinicke_studie_sukl_posouva_h2_global_group_do_centra_&utm_medium=email&utm_term=30027&ecmid=23486

H2 Longevity®: The Czech Hydrogen-Based Longevity Revolution Conquering the World

H2 Longevity®: The Czech Hydrogen-Based Longevity Revolution Conquering the World

by | Oct 19, 2025 | Health

The Czech company H2 Global Group, a world leader in the HealthTech and MedTech sectors with more than 13 years of research and development in the field of Molecular Hydrogen®, presents its latest exclusive project – the H2 Longevity® longevity center.

 

This innovative project combines science, modern technologies, and an exclusive wellness experience into one concept that transforms how people approach health, energy, and performance.

“We are following the trend. Customers want individual care for body and mind. Our hydrogen rituals within the H2 Longevity® project are the answer to this demand. It’s a form of biohacking with hydrogen – a modern approach that uses scientifically proven methods to optimize healthy body function, regeneration, and both mental and physical performance.
We are the only ones in the world who can comprehensively, safely, and effectively combine the effects of hydrogen, science, wellness, and experience into one functional system,”
says David Maršálek, founder and CEO of H2 Global Group.

 

A new symbol of health, vitality, and longevity

H2 Longevity® Ostrava is the first next-generation longevity center and the result of many years of research and know-how by the H2 Global Group team. The goal is to build a network of similar centers worldwide in cooperation with partners and distributors.

The program is based on scientific findings and delivers measurable results — from cell regeneration and performance enhancement to slowing down the aging process and harmonizing body and mind.
The next development phase of H2 Longevity® will include diagnostic measurements that allow clients to understand their body’s condition and receive precise recommendations for personalized care.

H2 Longevity® as a lifestyle – the path to healthy longevity

The project offers a personalized approach and is designed not only for distributors and partners but also for companies that wish to provide employees with modern health and regeneration benefits through corporate wellness zones — with an emphasis on injury prevention, stress reduction, and sustainable performance.

H2 Longevity® is also ideal for sports clubs, fitness centers, beauty salons, and rehabilitation facilities seeking to offer the most advanced form of regeneration and biohacking through the correct and safe use of Molecular Hydrogen® at a global standard.

“Customers, distributors, partners, and investors understand that H2 Longevity® is not just another wellness trend but a new global wave of health, science, and exclusivity. Our goal is to connect the world under a brand that carries a Czech signature with global significance,”
adds David Maršálek.

The project already has a global dimension, and new partners from around the world are expressing interest in collaboration.
H2 Global Group’s technologies are already used by thousands of customers, clients, and distributors in the Czech Republic, Slovakia, Germany, Spain, England, the USA, and Hong Kong, and the expansion continues.

The fusion of science and functional solutions

H2 Longevity® offers H2 Ritual Collection wellness rituals combining hydrogen inhalation, red light therapy, bottled hydrogen water (H2 Premium®), nutritional supplements (H2 Brain® and H2 Forte®), and skincare treatments.

These procedures use devices developed by H2 Medical Technologies, a subsidiary of H2 Global Group, which is the exclusive supplier of professional hydrogen generators and inhalers for wellness centers, spas, private clinics, medical facilities, and even home use.

The development roadmap also includes patented hydrogen-based cosmetics, scheduled for official market launch in early 2026.
Together, these elements form a comprehensive ecosystem of body and mind care, unparalleled anywhere in the world.

H2 Global Group – a company transforming medicine

The company is also active in medical research and development.
Its subsidiary H2 Medical Technologies has developed a prototype of the world’s first medical device for controlled hydrogen therapy, designed for people with mild cognitive impairment (MCI) — a condition that often precedes Alzheimer’s dementia.
The goal is to register the device as a certified medical product and include it in public health insurance coverage in the near future.

This technology, developed under a patent by Japanese scientist Professor Shigeo Ohta, co-founder of H2 Global Group, was presented in September at the prestigious LSI Europe 2025 international conference for investors and innovators in London, where it attracted significant attention from both investors and professionals.

H2 Global Group recognizes its social responsibility, which includes bringing innovations that improve health, vitality, and quality of life for people worldwide.
At the same time, it offers opportunities for investors, partners, and distributors who want to be part of the revolution in health, science, and longevity.

“Hydrogen is the molecule of life that connects the world. We are proud that it is from the Czech Republic that we bring solutions improving the quality of life for millions of people,”
concludes David Maršálek, CEO and founder of H2 Global Group.

H2 Longevity® Center Ostrava now open to the public

The newly opened H2 Longevity® Center in Ostrava invites the general public to experience first-hand modern health and longevity technologies.
Every visitor can now enjoy a first visit free of charge and personally experience the effects of molecular hydrogen in combination with light therapy and other exclusive procedures.

Clients can later participate in regular care programs focused on performance, regeneration, and harmony of body and mind — both locally and with partner centers.
Thus, H2 Longevity® Ostrava becomes a place where the science of health transforms into personal experience.

Source:
Metro.cz – PROTEXT: H2 Longevity®: The Czech Hydrogen Longevity Revolution Conquers the World

H2 Global Group
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.